

Supplementary Table 1. Patients' characteristics between pCR and non-pCR group

covar	levels	pCR	non-pCR	Total	Chisquared test p-value
Age category	≤50 yrs	99(19.8%)	400(80.2%)	499(50.0%)	0.583
	>50 yrs	106(21.2%)	393(78.8%)	499(50.0%)	
Race	WHITE	118(19.4%)	491(80.6%)	609(61.0%)	0.001
	BLACK	23(14.6%)	134(85.4%)	157(15.7%)	
	HISPANIC	53(31.9%)	113(68.1%)	166(16.6%)	
	OTHER	11(16.7%)	55(83.3%)	66(6.6%)	
Menopause	POST	115(21.5%)	420(78.5%)	535(53.8%)	0.413
	PRE	89(19.4%)	370(80.6%)	459(46.2%)	
Type	IBC	172(21.7%)	622(78.3%)	794(79.6%)	0.084
	nonIBC	33(16.2%)	171(83.8%)	204(20.4%)	
Clinical Stage	III/IIIA	54(18.2%)	242(81.8%)	296(29.7%)	0.001
	IIIB	38(14.7%)	221(85.3%)	259(26.0%)	
	IIIC	113(25.5%)	330(74.5%)	443(44.4%)	
Nuclear grade	I/II	30(10.6%)	253(89.4%)	283(29.6%)	<0.001
	III	165(24.5%)	508(75.5%)	673(70.4%)	
ER	Negative	120(33.2%)	241(66.8%)	361(36.3%)	<0.001
	Positive	83(13.1%)	551(86.9%)	634(63.7%)	
PR	Negative	156(29.0%)	382(71.0%)	538(54.3%)	<0.001
	Positive	44(9.7%)	408(90.3%)	452(45.7%)	
HER2	2+FISH Unknown	1(5.9%)	16(94.1%)	17(1.7%)	<0.001
	NEG	92(12.6%)	641(87.4%)	733(73.4%)	
	POS	112(45.2%)	136(54.8%)	248(24.8%)	
Baseline BMI	1: ~25	63(24.0%)	199(76.0%)	262(26.3%)	0.243
	2: 25~30	59(18.6%)	258(81.4%)	317(31.8%)	
	3: >30	83(19.8%)	336(80.2%)	419(42.0%)	
BMI change	<0	97(18.2%)	435(81.8%)	532(53.3%)	0.054
	≥0	108(23.2%)	358(76.8%)	466(46.7%)	

pCR (pathological complete response) was defined as having no residual invasive carcinoma in

the breast and no tumor in the axillary lymph nodes